PBMC from ADF may be characterized by an impaired response induced by Aβ and by a reduced proliferative response responsible for the longer telomeres. TL might be a contributing factor in predicting the rate of AD progression.

Abstract. We investigated IL-10 and IL-6 production in amyloid-␤ (A␤) stimulated peripheral blood mononuclear cells (PBMCs) in twenty Alzheimer's disease (AD) patients with slow progression, eleven with fast progression, and twenty age-matched controls. Promoter polymorphisms in IL-10 (position −592, −819, −1082), IL-6 (−174), transforming growth factor-␤1 (TGF-␤1) (−10, −25), interferon-␥ (IFN-␥) (−874), and tumor necrosis factor-␣ (TNF-␣) (−308) genes were analyzed. IL-10 production after A␤ stimulation was high in PBMCs from slow decliners and almost completely abrogated in fast decliners. Association between AA IFN-␥ low-producing genotype and fast progression was demonstrated. Investigations in a larger sample will clarify these findings.

IntroductionCrotoxin has a broad antitumor activity but has shown frequent neurotoxic toxicity. To induce tolerance and limit this toxicity, we propose a new design with intra-patient dose escalation.MethodsA new Dose Limiting Toxicity definition was used. The concept of Target Ceiling Dose was introduced.ResultsDose Limiting Toxicity was the inability to dose escalate twice. Target Ceiling Dose was the highest planned dose to be administered to a patient and could change for patients along time. Recommended Dose was defined similarly as in a (3 + 3) conventional design.ConclusionThis innovant design was used and the clinical trial is now closed for inclusions. Results will be presented later.

No abstract

No abstract